View More Recent Stories
-
Oruka Therapeutics, Inc. (ORKA) Reports Q3 Loss of $1.46
-
Stifel Starts Oruka Therapeutics (ORKA) at Buy
-
H.C. Wainwright Starts Oruka Therapeutics (ORKA) at Buy, 'Less (Injections) Is More; Derm Disruption'
-
TD Cowen Reiterates Buy Rating on Oruka Therapeutics (ORKA)
-
Oruka Therapeutics (ORKA) Reports Preclinical Data for ORKA-001
-
LifeSci Capital Starts Oruka Therapeutics (ORKA) at Outperform
-
TD Cowen Starts Oruka Therapeutics (ORKA) at Buy
-
Jefferies Starts Oruka Therapeutics (ORKA) at Buy
-
Oruka Therapeutics (ORKA) Announces $200 Million Private Placement
-
Oruka Therapeutics (ORKA) Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile

